Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123660131> ?p ?o ?g. }
- W3123660131 endingPage "118" @default.
- W3123660131 startingPage "1" @default.
- W3123660131 abstract "Background Persistent throat symptoms are commonly attributed to ‘laryngopharyngeal reflux’. Despite a limited evidence base, these symptoms are increasingly being treated in primary care with proton pump inhibitors. Objective To assess the value of proton pump inhibitor therapy in patients with persistent throat symptoms. Design This was a double-blind, placebo-controlled, randomised Phase III trial. Setting This was a multicentre UK trial in eight UK ear, nose and throat departments. Participants A total of 346 participants aged ≥ 18 years with persistent throat symptoms and a Reflux Symptom Index score of ≥ 10, exclusive of the dyspepsia item, were recruited. Intervention Random allocation (1 : 1 ratio) to either 30 mg of lansoprazole twice daily or matched placebo for 16 weeks. Main outcome measure Symptomatic response (i.e. total Reflux Symptom Index score after 16 weeks of therapy). Results A total of 1427 patients were screened and 346 were randomised. The mean age was 52 years (standard deviation 13.7 years, range 20–84 years); 150 (43%) participants were male and 196 (57%) were female; 184 (53%) participants had a mild Reflux Symptom Index minus the heartburn/dyspepsia item and 162 (47%) had a severe Reflux Symptom Index minus the heartburn/dyspepsia item. A total of 172 patients were randomised to lansoprazole and 174 were randomised to placebo. Main outcomes A total of 267 participants completed the primary end-point visit (lansoprazole, n = 127; placebo, n = 140), of whom 220 did so between 14 and 20 weeks post randomisation (‘compliant’ group); 102 received lansoprazole and 118 received placebo. The mean Reflux Symptom Index scores at baseline were similar [lansoprazole 22.0 (standard deviation 8.0), placebo 21.7 (standard deviation 7.1), overall 21.9 (standard deviation 7.5)]. The mean Reflux Symptom Index scores at 16 weeks reduced from baseline in both groups [overall 17.4 (standard deviation 9.9), lansoprazole 17.4 (standard deviation 9.9), placebo 15.6 (standard deviation 9.8)]. Lansoprazole participants had estimated Reflux Symptom Index scores at 16 weeks that were 1.9 points higher (worse) than those of placebo participants (95% confidence interval –0.3 to 4.2; p adj = 0.096), adjusted for site and baseline severity. Secondary outcomes Ninety-five (43%) participants achieved a Reflux Symptom Index score in the normal range (< 12) at 16 weeks: 42 (41%) in the lansoprazole group and 53 (45%) in the placebo group. A total of 226 participants completed the end-of-trial follow-up visit (lansoprazole, n = 109; placebo, n = 117), of whom 181 were ‘compliant’. The mean Reflux Symptom Index scores at 12 months reduced from baseline in both groups [lansoprazole 16.0 (standard deviation 10.8), placebo 13.6 (standard deviation 9.6), overall 14.7 (standard deviation 10.2)]. A total of 87 (48%) participants achieved a Reflux Symptom Index score in the normal range at 12 months: 33 (40%) in the lansoprazole group and 54 (55%) in the placebo group. Likewise, the Comprehensive Reflux Symptom Score and Laryngopharyngeal Reflux – Health Related Quality of Life total scores and subscales all showed very similar changes in the lansoprazole and placebo cohorts at both 16 weeks and 12 months. Limitations Drop-out rate and compliance are issues in pragmatic clinical trials. The Trial Of Proton Pump Inhibitors in Throat Symptoms (TOPPITS) aimed to detect clinically relevant difference with 90% power. The 346 randomised participants reduced to 283 at the primary end point; 267 completed the primary outcome measure, 220 within the protocol time scale. Despite this, the powers to detect the clinically relevant difference in Reflux Symptom Index score at 16 weeks were 82% (compliant comparison) and 89% (pragmatic comparison). The lack of difference between lansoprazole and placebo is generalisable across NHS clinics. Conclusions Participants on lansoprazole did not report significantly better outcomes than participants on placebo on any of the three patient-reported outcome tools (Reflux Symptom Index, Comprehensive Reflux Symptom Score and Laryngopharyngeal Reflux – Health Related Quality of Life). This multicentre, pragmatic, powered, definitive Phase III trial found no evidence of benefit for patients by treating persistent throat symptoms with lansoprazole. Trial registration Current Controlled Trials ISRCTN38578686 and EudraCT number 2013-004249-17. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 25, No. 3. See the NIHR Journals Library website for further project information." @default.
- W3123660131 created "2021-02-01" @default.
- W3123660131 creator A5003600185 @default.
- W3123660131 creator A5007847728 @default.
- W3123660131 creator A5009180137 @default.
- W3123660131 creator A5009516533 @default.
- W3123660131 creator A5020335882 @default.
- W3123660131 creator A5023057149 @default.
- W3123660131 creator A5026274050 @default.
- W3123660131 creator A5031341088 @default.
- W3123660131 creator A5040845650 @default.
- W3123660131 creator A5047073496 @default.
- W3123660131 creator A5055065622 @default.
- W3123660131 creator A5064200945 @default.
- W3123660131 creator A5064863331 @default.
- W3123660131 creator A5068628861 @default.
- W3123660131 creator A5080522473 @default.
- W3123660131 date "2021-01-01" @default.
- W3123660131 modified "2023-10-10" @default.
- W3123660131 title "Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT" @default.
- W3123660131 cites W1008047686 @default.
- W3123660131 cites W1527288746 @default.
- W3123660131 cites W1549176720 @default.
- W3123660131 cites W1565457160 @default.
- W3123660131 cites W1779213511 @default.
- W3123660131 cites W1787340360 @default.
- W3123660131 cites W1847119802 @default.
- W3123660131 cites W1955307858 @default.
- W3123660131 cites W1964588845 @default.
- W3123660131 cites W1964624082 @default.
- W3123660131 cites W1967370656 @default.
- W3123660131 cites W1968741676 @default.
- W3123660131 cites W1971576283 @default.
- W3123660131 cites W1973649283 @default.
- W3123660131 cites W1979168354 @default.
- W3123660131 cites W1981661409 @default.
- W3123660131 cites W1985162593 @default.
- W3123660131 cites W1986172404 @default.
- W3123660131 cites W1987858036 @default.
- W3123660131 cites W1989203314 @default.
- W3123660131 cites W1990275434 @default.
- W3123660131 cites W1992355265 @default.
- W3123660131 cites W1992511384 @default.
- W3123660131 cites W1997013285 @default.
- W3123660131 cites W1997256477 @default.
- W3123660131 cites W2000124508 @default.
- W3123660131 cites W2000188036 @default.
- W3123660131 cites W2006012652 @default.
- W3123660131 cites W2011310913 @default.
- W3123660131 cites W2015276969 @default.
- W3123660131 cites W2023366362 @default.
- W3123660131 cites W2025079998 @default.
- W3123660131 cites W2027952056 @default.
- W3123660131 cites W2032489783 @default.
- W3123660131 cites W2033331340 @default.
- W3123660131 cites W2035516047 @default.
- W3123660131 cites W2042653115 @default.
- W3123660131 cites W2043872498 @default.
- W3123660131 cites W2046163043 @default.
- W3123660131 cites W2047191698 @default.
- W3123660131 cites W2049932633 @default.
- W3123660131 cites W2054762785 @default.
- W3123660131 cites W2062379863 @default.
- W3123660131 cites W2064464346 @default.
- W3123660131 cites W2064510469 @default.
- W3123660131 cites W2064921125 @default.
- W3123660131 cites W2068430670 @default.
- W3123660131 cites W2068747151 @default.
- W3123660131 cites W2077096785 @default.
- W3123660131 cites W2077836318 @default.
- W3123660131 cites W2081011525 @default.
- W3123660131 cites W2082384047 @default.
- W3123660131 cites W2085640914 @default.
- W3123660131 cites W2086830088 @default.
- W3123660131 cites W2088572214 @default.
- W3123660131 cites W2089412742 @default.
- W3123660131 cites W2089852982 @default.
- W3123660131 cites W2093064790 @default.
- W3123660131 cites W2096578110 @default.
- W3123660131 cites W2101164472 @default.
- W3123660131 cites W2104760346 @default.
- W3123660131 cites W2113443314 @default.
- W3123660131 cites W2117722911 @default.
- W3123660131 cites W2118684174 @default.
- W3123660131 cites W2122545470 @default.
- W3123660131 cites W2130055143 @default.
- W3123660131 cites W2132295905 @default.
- W3123660131 cites W2140190193 @default.
- W3123660131 cites W2143160997 @default.
- W3123660131 cites W2148792541 @default.
- W3123660131 cites W2151011199 @default.
- W3123660131 cites W2154477517 @default.
- W3123660131 cites W2156520550 @default.
- W3123660131 cites W2158817822 @default.
- W3123660131 cites W2206426110 @default.
- W3123660131 cites W2227230631 @default.
- W3123660131 cites W2313719515 @default.
- W3123660131 cites W2314404046 @default.